Leishmaniasis worldwide and global estimates of its incidence

Jorge Alvar, Iván D Vélez, Caryn Bern, Mercé Herrero, Philippe Desjeux, Jorge Cano, Jean Jannin, Margriet den Boer, WHO Leishmaniasis Control Team, Daniel Argaw, Sujit Bhattacharya, Mikhail Ejov, Ana Nilce Elkhouri, José Antonio Ruiz-Postigo, Joseph Serrano, Jorge Alvar, Iván D Vélez, Caryn Bern, Mercé Herrero, Philippe Desjeux, Jorge Cano, Jean Jannin, Margriet den Boer, WHO Leishmaniasis Control Team, Daniel Argaw, Sujit Bhattacharya, Mikhail Ejov, Ana Nilce Elkhouri, José Antonio Ruiz-Postigo, Joseph Serrano

Abstract

As part of a World Health Organization-led effort to update the empirical evidence base for the leishmaniases, national experts provided leishmaniasis case data for the last 5 years and information regarding treatment and control in their respective countries and a comprehensive literature review was conducted covering publications on leishmaniasis in 98 countries and three territories (see 'Leishmaniasis Country Profiles Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21, S22, S23, S24, S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S65, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, S100, S101'). Additional information was collated during meetings conducted at WHO regional level between 2007 and 2011. Two questionnaires regarding epidemiology and drug access were completed by experts and national program managers. Visceral and cutaneous leishmaniasis incidence ranges were estimated by country and epidemiological region based on reported incidence, underreporting rates if available, and the judgment of national and international experts. Based on these estimates, approximately 0.2 to 0.4 cases and 0.7 to 1.2 million VL and CL cases, respectively, occur each year. More than 90% of global VL cases occur in six countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil. Cutaneous leishmaniasis is more widely distributed, with about one-third of cases occurring in each of three epidemiological regions, the Americas, the Mediterranean basin, and western Asia from the Middle East to Central Asia. The ten countries with the highest estimated case counts, Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru, together account for 70 to 75% of global estimated CL incidence. Mortality data were extremely sparse and generally represent hospital-based deaths only. Using an overall case-fatality rate of 10%, we reach a tentative estimate of 20,000 to 40,000 leishmaniasis deaths per year. Although the information is very poor in a number of countries, this is the first in-depth exercise to better estimate the real impact of leishmaniasis. These data should help to define control strategies and reinforce leishmaniasis advocacy.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria. PLoS Med. 2006;3:e102.
    1. Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, et al. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis. 2004;38:871–878.
    1. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006;22:552–557.
    1. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008;2:e313.
    1. World Health Assembly. Geneva, Switzerland; 2007. The World Health Assembly Resolution (WHA60.13) on the “Control of Leishmaniasis”.5
    1. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010;949:186.
    1. Murray C, Lopez A, editors. 1022 p; 1996. Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 Cambridge, MA: Harvard University Press.
    1. Cattand P, Desjeux P, Guzman MG, Jannin J, Kroeger A, et al. Chapter 23. Tropical Diseases Lacking Adequate Control Measures: Dengue, Leishmaniasis and African Trypanosomiasis. In: Jamison DT, Bremen JG, Measham AR, Alleyne G, Claeson M, et al., editors. Disease Control Priorities in Developing Countries. Washington, D.C.: The World Bank and Oxford University Press; 2006. pp. 451–466.
    1. Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis. 2007;1:e114.
    1. World Health Organization. Geneva, Switzerland: World Health Organization; 2008. The Global Burden of Disease: 2004 update.84
    1. World Bank. New York: Oxford University Press; 1993. Investing in Health: World Development Report 1993.84
    1. AbouZahr C, Vaughan JP. Assessing the burden of sexual and reproductive ill-health: questions regarding the use of disability-adjusted life years. Bull World Health Organ. 2000;78:655–666.
    1. King CH, Bertino AM. Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Negl Trop Dis. 2008;2:e209.
    1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365:1561–1569.
    1. Institute for Health Metrics and Evaluation. 2010. Global Burden of Diseases, Injuries, and Risk Factors Study. Available: . Accessed 10/12/2011.
    1. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet. 2010;375:239–247.
    1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996;14:417–423.
    1. Sen Gupta PC. History of kala-azar in India. Indian Medical Gazette. 1947;82:281–286.
    1. Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis. 2005;11:655–662.
    1. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004;38:612–619.
    1. Rey LC, Martins CV, Ribeiro HB, Lima AA. American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area. J Pediatr (Rio J) 2005;81:73–78.
    1. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg. 1994;51:826–836.
    1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27:305–318.
    1. Copeland HW, Arana BA, Navin TR. Comparison of active and passive case detection of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990;43:257–259.
    1. Maia-Elkhoury AN, Carmo EH, Sousa-Gomes ML, Mota E. [Analysis of visceral leishmaniasis reports by the capture-recapture method]. Rev Saude Publica. 2007;41:931–937.
    1. Mosleh IM, Geith E, Natsheh L, Abdul-Dayem M, Abotteen N. Cutaneous leishmaniasis in the Jordanian side of the Jordan Valley: severe under-reporting and consequences on public health management. Trop Med Int Health. 2008;13:855–860.
    1. Singh SP, Reddy DC, Rai M, Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health. 2006;11:899–905.
    1. Singh VP, Ranjan A, Topno RK, Verma RB, Siddique NA, et al. Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg. 2010;82:9–11.
    1. Yadon ZE, Quigley MA, Davies CR, Rodrigues LC, Segura EL. Assessment of Leishmaniasis notification system in Santiago del Estero, Argentina, 1990–1993. Am J Trop Med Hyg. 2001;65:27–30.
    1. Reithinger R, Mohsen M, Aadil K, Sidiqi M, Erasmus P, et al. Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan. Emerg Infect Dis. 2003;9:727–729.
    1. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol. 2000;30:1269–1281.
    1. Ashford R, Bettini S. Ecology and epidemiology: Old World. In: Peters W, Killick-Kendrick R, editors. The Leishmaniases in Biology and Medicine. London, UK: Academic Press; 1987. pp. 366–424.
    1. Shaw J, Lainson R. Ecology and epidemiology: New World. In: Peters W, Killick-Kendrick R, editors. The Leishmaniases in Biology and Medicine. London, UK: Academic Press; 1987. pp. 292–363.
    1. World Bank. 2011. Countries and Economies. Washington, D.C. Available: . Accessed: 10/12/2011.
    1. World Bank. 2011. Indicators. Washington, D.C. Available: . Accessed: 10/12/2011.
    1. United Nations Development Programme. 2011. Human Development Report 2011. New York, NY. Available: : 10/12/2011.
    1. World Health Organization. 2011. WHO Statistical Information System. Geneva, Switzerland. Available: : 10/12/2011.
    1. International Monetary Fund. 2011. World Economic and Financial Surveys. New York, NY. Available: Accessed: 10/12/2011.
    1. le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:1953–1957.
    1. Neronov VM, Strelkova MV, Shurkhal AA, Luschekina AA, Artemyev MM. Natural focality of zoonotic cutaneous leishmaniasis in the Mongolian People’s Republic; results and objectives of integrated research. Folia Parasitol (Praha) 1987;34:1–9.
    1. Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, et al. Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms. Int J Parasitol. 2004;34:655–664.
    1. Chicharro C, Alvar J. Lower trypanosomatids in HIV/AIDS patients. Ann Trop Med Parasitol. 2003;97(Suppl 1):75–78.
    1. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. American Journal of Tropical Medicine and Hygiene. 2003;69:624–628.
    1. Kumar R, Kumar P, Chowdhary RK, Pai K, Mishra CP, et al. Kala-azar epidemic in Varanasi district, India. Bull World Health Organ. 1999;77:371–374.
    1. Barnett P, Singh SP, Bern C, Hightower AW, Sundar S. Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg. 2005;73:720–725.
    1. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol. 1996;25:862–871.
    1. Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen Kala-azar deaths in south Sudan (1999–2002). Trop Med Int Health. 2006;11:509–512.
    1. Ashford RW, Desjeux P, deRaadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitology Today. 1992;8:104–105.
    1. Desjeux P. Information on the epidemiology and control of the leishmaniases by country or territory. Geneva: World Health Organization. WHO/LEISH. 1991;91.30:47.
    1. Yamey G, Torreele E. The world’s most neglected diseases [editorial]. British Medical Journal. 2002;325:176–177.
    1. Narain JP, Dash AP, Parnell B, Bhattacharya SK, Barua S, et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. Bull World Health Organ. 2010;88:206–210.
    1. Hirve S, Singh SP, Kumar N, Banjara MR, Das P, et al. Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, bangladesh, and Nepal. Am J Trop Med Hyg. 2010;83:507–511.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera